Loading...
XNAS
VYNE
Market cap11mUSD
Jul 09, Last price  
0.67USD
1D
3.35%
1Q
10.16%
IPO
-99.97%
Name

Vyne Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:VYNE chart
P/E
—
P/S
19.65
EPS
—
Div Yield, %
—
Shrs. gr., 5y
88.42%
Rev. gr., 5y
-51.39%
Revenues
570k
+13.77%
0674,0004,582,00010,640,000443,00020,993,000931,000477,000424,000501,000570,000
Net income
-26m
L-33.52%
-4,608,000-14,068,000-29,076,000-51,445,000-70,464,000-255,568,000-73,329,000-23,210,000-28,452,000-39,834,000-26,483,000
CFO
-33m
L-2.50%
-4,183,000-2,291,000-28,247,000-52,733,000-65,101,000-137,082,000-56,367,000-29,200,000-25,341,000-33,972,000-33,124,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.
URL
https://vynetherapeutics.com/
IPO date
Jan 25, 2018
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT